更新版序贯器官衰竭评估(SOFA)-2评分在急诊脓毒性休克中的验证
本研究为观察性研究,分析两个前瞻性脓毒性休克注册队列,纳入成人急诊脓毒性休克患者,使用急诊前24小时最差生理和实验室值计算SOFA-1与SOFA-2。队列A(2669例)和队列B(1443例)中,SOFA-2对院内、28天、90天死亡率的AUROC均显著高于SOFA-1(均p<0.001),校准曲线更接近,Brier评分更低,连续NRI和IDI均支持SOFA-2。结论支持SOFA-2在急诊脓毒性休克人群的外部验证,需在多样急诊环境中进一步评估。
要点
- 在急诊脓毒性休克成人患者中,SOFA-2对院内死亡率的AUROC在队列A为0.734(vs SOFA-1 0.702),队列B为0.719(vs 0.671),均p<0.001。
- SOFA-2对28天死亡率AUROC:队列A 0.719 vs 0.694,队列B 0.737 vs 0.689;90天死亡率:队列A 0.680 vs 0.658,队列B 0.711 vs 0.666(均p<0.001)。
- SOFA-2的校准曲线显示预测与观察院内死亡率更接近,Brier评分更低;连续NRI为0.276-0.635,IDI为0.024-0.062(均p<0.001)。
- 校正分析中,SOFA-2每增加1分与更高死亡率独立相关;敏感性和汇总分析结果一致。
- SOFA-1与SOFA-2评分分布差异显著,但两种评分下死亡率均随评分升高而增加。
适用人群与场景
- 成人急诊脓毒性休克患者,来自两个前瞻性脓毒性休克注册队列(队列A 2669例,队列B 1443例)。
- 排除人群:原文未提及。
诊断标准与关键阈值
- SOFA-1和SOFA-2评分均使用急诊前24小时内记录的最差生理和实验室值计算。
- SOFA-2为近期更新的数据驱动评分,修订了组分阈值并纳入当代器官支持模式;具体阈值原文未详述。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 主要终点:SOFA-2对院内死亡率的AUROC在队列A为0.734(vs SOFA-1 0.702),队列B为0.719(vs 0.671),均p<0.001。
- 关键次要终点:SOFA-2对28天死亡率AUROC队列A 0.719 vs 0.694,队列B 0.737 vs 0.689;90天死亡率队列A 0.680 vs 0.658,队列B 0.711 vs 0.666(均p<0.001)。
- 校准:SOFA-2预测与观察院内死亡率更接近,Brier评分更低;连续NRI 0.276-0.635,IDI 0.024-0.062(均p<0.001)。
- 校正分析中SOFA-2每增加1分与更高死亡率独立相关;敏感性和汇总分析结果一致。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:观察性研究,基于两个前瞻性注册队列的外部验证。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未明确列出局限;设计上为观察性研究,仅在两个注册队列中验证,需在多样急诊环境中进一步评估(原文结论提及)。
对床旁实践的改变
- 在急诊脓毒性休克患者中,使用急诊前24小时最差值计算的SOFA-2较SOFA-1对院内、28天和90天死亡率的区分度略有提高,校准更佳,可考虑用于风险分层。
- SOFA-2每增加1分与更高死亡率独立相关,但原文未给出具体决策阈值,不能据此设定启动或停止治疗的界值。
- 适用人群为成人急诊脓毒性休克患者;不适用人群及常见陷阱原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The original Sequential Organ Failure Assessment (SOFA-1) score is widely used to quantify organ dysfunction in critically ill patients, including those with septic shock. A recently updated, data-driven SOFA score (SOFA-2) revises component thresholds and incorporates contemporary organ support modalities. While SOFA-2 has been validated in intensive care unit populations, its performance in the emergency department (ED), particularly among patients with septic shock, is uncertain. We therefore sought to validate SOFA-2 in ED patients with septic shock.
METHODS: In this observational study, we analyzed two prospective septic shock registries. Adult ED patients with septic shock were included. SOFA-1 and SOFA-2 scores were calculated using the worst physiologic and laboratory values recorded within the first 24 h in the ED. We compared score distributions and examined mortality across score ranges. Discrimination for in-hospital, 28-day, and 90-day mortality was evaluated using the area under the receiver operating characteristic curve (AUROC). Calibration for in-hospital mortality was assessed using the calibration curve and Brier scores. Reclassification performance was evaluated using continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI).
RESULTS: The study included 2669 patients in Cohort A and 1443 patients in Cohort B. SOFA-1 and SOFA-2 score distributions differed significantly. Mortality generally increased with higher SOFA-1 and SOFA-2 scores across all outcomes. SOFA-2 demonstrated significantly higher AUROCs than SOFA-1 for in-hospital, 28-day, and 90-day mortality in both cohorts (Cohort A: 0.734 vs. 0.702, 0.719 vs. 0.694, and 0.680 vs. 0.658; Cohort B: 0.719 vs. 0.671, 0.737 vs. 0.689, and 0.711 vs. 0.666; all p < 0.001). SOFA-2 showed generally closer agreement between predicted and observed in-hospital mortality and lower Brier scores. Continuous NRI (0.276-0.635) and IDI (0.024-0.062) also favored SOFA-2 across all mortality outcomes (all p < 0.001). In adjusted analyses, each 1-point increase in SOFA-2 was independently associated with higher mortality. Sensitivity analyses and pooled analyses showed consistent findings.
CONCLUSION: Among ED patients with septic shock, SOFA-2 showed modestly improved discrimination, closer agreement between predicted and observed in-hospital mortality with lower overall prediction error, and more favorable continuous reclassification metrics compared with SOFA-1. These findings support the external validation of SOFA-2 in this population and warrant further evaluation in diverse ED settings.
参考来源
- Ahn S, Kim SM, Park JH, et al. Validation of the updated sequential organ failure assessment (SOFA)-2 score in emergency department septic shock. J Intensive Care. 2026. PMID: 42687193. doi:10.1186/s40560-026-00921-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。